Nothing Special   »   [go: up one dir, main page]

MX2021002884A - Terapia de combinacion para el tratamiento de cancer de prostata. - Google Patents

Terapia de combinacion para el tratamiento de cancer de prostata.

Info

Publication number
MX2021002884A
MX2021002884A MX2021002884A MX2021002884A MX2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A MX 2021002884 A MX2021002884 A MX 2021002884A
Authority
MX
Mexico
Prior art keywords
prostate cancer
treatment
combination therapy
combination
faromadomain
Prior art date
Application number
MX2021002884A
Other languages
English (en)
Inventor
Eric Campeau
Sanjay Lakhotia
Sarah Christine Attwell
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of MX2021002884A publication Critical patent/MX2021002884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención proporciona métodos para tratar el cáncer de próstata, incluido el cáncer de próstata resistente a la castración metastásico, que comprende administrar a un sujeto que lo necesite un inhibidor de bromodominio BET en combinación con un segundo agente.
MX2021002884A 2018-09-13 2019-09-13 Terapia de combinacion para el tratamiento de cancer de prostata. MX2021002884A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862730869P 2018-09-13 2018-09-13
US201862737612P 2018-09-27 2018-09-27
US201862778185P 2018-12-11 2018-12-11
PCT/US2019/050970 WO2020056232A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX2021002884A true MX2021002884A (es) 2021-07-15

Family

ID=69778254

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002884A MX2021002884A (es) 2018-09-13 2019-09-13 Terapia de combinacion para el tratamiento de cancer de prostata.

Country Status (12)

Country Link
US (1) US20220117942A1 (es)
EP (1) EP3849544A4 (es)
JP (1) JP7441214B2 (es)
KR (1) KR20210060515A (es)
CN (1) CN112912075B (es)
AU (1) AU2019338483B2 (es)
CA (1) CA3112396A1 (es)
IL (1) IL281281A (es)
MX (1) MX2021002884A (es)
SG (1) SG11202102492PA (es)
TW (1) TWI816880B (es)
WO (1) WO2020056232A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202024078A (zh) 2018-09-13 2020-07-01 加拿大商增你智表觀遺傳學公司 Bet溴結構域(bromodomain)抑制劑之固體形式之製備方法
WO2022178226A1 (en) * 2021-02-22 2022-08-25 Celgene Quanticel Research, Inc. Bromodomain (bet) inhibitor for use in treating prostate cancer
CN114644687B (zh) * 2022-04-07 2023-06-27 华中科技大学同济医学院附属协和医院 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
SI3010503T1 (sl) * 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP3062808B1 (en) * 2013-10-28 2021-09-29 The Regents of the University of California Treatment of metastatic prostate cancer
NO2719005T3 (es) * 2014-07-28 2018-01-20
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
US20180141939A1 (en) * 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
US20180153867A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent

Also Published As

Publication number Publication date
SG11202102492PA (en) 2021-04-29
US20220117942A1 (en) 2022-04-21
JP7441214B2 (ja) 2024-02-29
AU2019338483B2 (en) 2025-01-02
EP3849544A4 (en) 2022-06-08
WO2020056232A1 (en) 2020-03-19
KR20210060515A (ko) 2021-05-26
CA3112396A1 (en) 2020-03-19
CN112912075A (zh) 2021-06-04
CN112912075B (zh) 2023-04-04
TW202017926A (zh) 2020-05-16
AU2019338483A1 (en) 2021-04-08
JP2022500431A (ja) 2022-01-04
EP3849544A1 (en) 2021-07-21
IL281281A (en) 2021-04-29
TWI816880B (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
PH12022551486A1 (en) Compounds and methods for the targeted degradation of androgen receptor
PH12017550063A1 (en) Combination therapies for treating cancers
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2016004489A (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
PH12016502354A1 (en) Pharmaceutical composition
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
MX2017015896A (es) Agente anticancerigeno.
MX2020001727A (es) Terapia de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2019013862A (es) Terapia de combinacion.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.